ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Since our previous study suggested that BCR-ABL mutation, especially T315I, cause metabolic alterations associated with changes in drug sensitivity [5, 9], we first test the effect of 2-deoxyglucose (2-DG), a glycolytic inhibitor that target HK, on the cytotoxic effect of IM in CML cells with BCR-ABL (KBM5 cell line) and with T315I mutation (KBM5-T315I cells), using both CCK-8 assay and direct cell counting.